Yinghong has broad business development experience ranging from early drug discovery to pre-clinical and clinical development. Prior to that, she was an integral team member of target selection, licensing & scientific network of MerckMillipore, responsible for lead evaluation and new product introduction.She started her drug discovery career as a medicinal chemist with additional expertise in computer aided drug design, working at biotech companies including Cytel Corporation, Neurocrine Biosciences and Arena Pharmaceuticals with increasing responsibilities. Her successful drug discovery track record is evidenced by over 30 publications and patents, multiple IND clinical candidates in different therapeutic areas and her indelible contributions to the discovery of Elagolix which led to the successful partnership with AbbVie and the recent FDA approval in 2018. She holds a MSc. Degree from Chinese Academy of Sciences in physical chemistry and a MSc. Degree from Tulane University in organic chemistry.